%0 Journal Article
%T 新辅助化疗与辅助化疗治疗肌层浸润性膀胱癌的疗效比较
%A 刘三河
%A 崔殿生
%A 贾全安
%A 邓康俐
%A 魏少忠
%A 黄雷
%J 肿瘤防治研究
%D 2019
%R 10.3971/j.issn.1000-8578.2019.18.1002
%X 摘要 目的 对接受新辅助和辅助化疗的膀胱癌患者临床疗效进行对比，为化疗时机的选择作初步探索。方法 回顾性研究湖北省肿瘤医院2009—2016年诊断为肌层浸润性膀胱癌并在全膀胱术前（新辅助）或术后（辅助）接受了GC方案化疗的患者。主要研究终点是无复发生存期（recurrencefree survival, RFS）。次要研究终点是临床完全缓解率（complete response, CR）。结果 共38例肌层浸润性膀胱癌患者纳入研究（22例新辅助+16例辅助）。在中位随访时间点时，新辅助和辅助化疗组的RFS相比较差异无统计学意义（69.6% vs.75.4%, P=0.223）。在中位随访时间点上接受新辅助化疗后病理完全缓解组（pT0）与非完全缓解组（non-pT0）的RFS分别为100%和50%（P=0.012），差异有统计学意义。两组患者在接受化疗治疗后出现3~4级严重血液学不良反应的人数比例相比较差异无统计学意义（P=0.36）。结论 接受新辅助或辅助化疗的肌层浸润性膀胱癌患者的RFS相比较差异无统计学意义，新辅助化疗后达到病理完全缓解的患者均未出现肿瘤复发，但尚需更多的研究来证实
%K An Update
%K Report on Six Cases of Invasive Bladder Cancer Treated with Natural Orifice Specimen Extraction Combined with Sigmoid Colon in situ Neo-bladder Surgery
%K Prognostic Effects of Different Courses of Neoadjuvant Chemotherapy on Stage N2-3 Locally Advanced Nasopharyngeal Carcinoma
%K Prognosis of Poorly-differentiated Gastric Neuroendocrine Neoplasm
%K Relationship of Integrinβ1 and CARMA-3 Protein Expressions with Recurrence of Bladder Cancer After Transurethral Resection of Bladder Tumor
%K Effectiveness of Neoadjuvant and Adjuvant Bladder Intracavitary Hyperthermic Perfusion Chemotherapy (BHPC) on High-risk Non-muscle-invasive Bladder Cancer Patients
%K Correlation Between 18F-FDG PET/CT SUVmax and Clinicopathological Features
%K Neoadjuvant Chemotherapy Response in Invasive Ductal Breast Carcinoma Patients
%K Correlation of FoxO3 Gene with Clinicopathological Features and Prognosis of Bladder Cancer Patients
%K Clinical Efficacy of Gemcitabine plus S-1 on Refractory Nasopharyngeal Carcinoma Patients and Their Influence on Immune Function
%K Prognostic Factors for Different Treatment Regimens in Advanced Epithelial Ovarian Cancer
%K Effect of Postoperative Chemotherapy on Prognosis of Postoperative Lymph Nodepositive Thoracic Esophageal Squamous Cell Carcinoma Patients
%K Mechanism About How Piceatannol Enhances Anti-tumor Effect of Cisplatin on Laryngeal Cancer Hep-2 Cells
%U http://www.zlfzyj.com/CN/abstract/abstract9381.shtml